Inozyme Pharma

$19.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.34 (+1.81%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Inozyme Pharma and other stocks, options, and ETFs commission-free!

About INZY

Inozyme Pharma engages in the research and development of novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Its lead product candidate is INZ-701, which is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.

CEO
Axel Bolte
Employees
—
Headquarters
Boston, Massachusetts
Founded
2015
Market Cap
471.01M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
52.90K
High Today
$19.33
Low Today
$18.31
Open Price
$18.57
Volume
26.17K
52 Week High
$31.65
52 Week Low
$16.10

INZY Earnings

-$7.57
-$5.05
-$2.52
$0.00
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 13, Pre-Market

You May Also Like

EPD
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure